Curis to Release Third Quarter 2009 Financial Results and Hold Conference Call on October 29, 2009

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter financial results on Thursday, October 29, 2009 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog Pathway Inhibitor program under collaboration with Genentech, (ii) its August 2009 license agreement with Debiopharm under which the Company’s Hsp90 inhibitor technologies, including Debio 0932 (formerly CUDC-305), were exclusively licensed, (iii) CUDC-101 and other proprietary targeted cancer programs, (iv) its financial results as of and for the three- and nine-month periods ended September 30, 2009, and (v) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call (800) 569-2037 from the United States or Canada or (617) 614-2713 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 77811969. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Thursday, November 5, 2009. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 60149533.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis’ website at www.curis.com.